Fibromyalgia is one of generalised pain syndromes including CFS and multiple bursitis-tendonitis syndrome. It's the most common cause of generalised pain affecting 2% of the popuation with a female to male ratio of up to 7:1. Hyperalgesia and allodynia are the characteristics of this diffuse pain which is often accompained by a wide range of symptoms, including fatigue, sleep disturbance, functional impairment, cognitive dysfunction, variable bowel habits, depression, stiffness, and more. FMS is characterised by maladaptive pain which has been demonstrated by fMRI scan and detailed somatosensory testing. It is a heterogenous syndrome regarding the symptoms. Depression is common, but it does not occur in all patients. Regardless this information, mood should be assessed in all patients. There is no assay or pathological test for it and the diagnosis is based on symptoms and exclusion of other illnesses. The American College of Rheumatology (ACR) 1990 classification criteria are commonly used as a diagnostic tool for FMS. Recently, the ACR published survey based diagnostic criteria for FMS which requires the presence of widespread pain for at least 3 months. However, tender point count has been replaced by a symptom checklist which includes the Widespread Pain Index and Symptom Severity Scale. As it can take up to 10 years before diagnosis, medical costs are high and thus it is very important to reduce them by a constructive diagnosis. Non-pharmacological interventions are important (e.g. graded exercise and warm water bath). Patients should be warned that pain may wprsen transiently when starting exercise, but they should preserve. Other options include cognitive-behavioral therapy, relaxation, rehabilitation, physiotherapy and psychological support, which may be used in some patients. Pharmacological treatments, as described in the EULAR recommendations, may be useful adjuncts to non-pharmacological treatments and should be considered. Choice will depend on clinical manifestations.